You are here: Industry Insights > Sarclisa

News List

EC approves new Sarclisa indication pharmatimes
April 20, 2021
The European Commission has approved Sanofi’s Sarclisa in combination with standard of care regimen carfilzomib and dexamethasone (Kd) for the treatment of relapsed multiple myeloma.
FDA green light for Sarclisa combo in multiple myeloma pharmatimes
April 01, 2021
French pharma company Sanofi has received US Food and Drug Administration (FDA) approval for its CD38 inhibitor Sarclisa in combination with carfilzomib and dexamethasone (Kd) for the treatment of advanced multiple myeloma.
NICE backs use of new treatment for multiple myeloma pharmatimes
November 27, 2020
Patients with a difficult to treat form of multiple myeloma will now gain access to a new treatment on the NHS in England and Wales, after cost regulators issued final guidance on the use of Sanofi's Sarclisa (isatuximab).
Sanofi's Sarclisa bags NICE recommendation pharmatimes
October 19, 2020
French pharma Sanofi’s Sarclisa has been granted a positive recommendation from the National Institute for Health and Care (NICE) for patients with multiple myeloma.
NICE rejects Sanofi's Sarclisa in preliminary guidelines pharmatimes
June 09, 2020
NICE has published initial guidelines rejecting NHS use of a therapy combination containing Sanofi's Sarclisa (isatuximab) to treat multiple myeloma.
Sanofi secures EC approval for Sarclisa for third-line multiple myeloma pharmaceutical-business-review
June 08, 2020
Sanofi has secured approval from the European Commission (EC) for Sarclisa (isatuximab) in combination with pomalidomide and dexamethasone (pom-dex) for the treatment of relapsed and refractory multiple myeloma (MM) in adult patients.
Sanofi gets EC approval for Sarclisa to treat multiple myeloma pharmaceutical-technology
June 04, 2020
Sanofi has received approval from the European Commission (EC) for the use of Sarclisa (isatuximab) with pomalidomide and dexamethasone (pom-dex) to treat adults with relapsed and refractory multiple myeloma (MM).
Sanofi’s blood cancer drug Sarclisa meets primary endpoint in IKEMA trial pharmaceutical-business-review
May 15, 2020
Sanofi said that its blood cancer drug Sarclisa (isatuximab) has achieved the primary goal of a phase 3 trial in patients with relapsed multiple myeloma.
Sanofi's Sarclisa cuts death risk in mutiple myeloma pharmatimes
May 13, 2020
Sanofi's monoclonal antibody Sarclisa (isatuximab) has hit targets in a late-stage trial, reducing the risk of disease progression or death in patients with relapsed multiple myeloma.
CHMP gives Sanofi positive opinion for Sarclisa pharmatimes
March 30, 2020
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Sarclisa (isatuximab).

Previous page 1 2 Next page